Header Logo

Connection

RITSUKO KOMAKI to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Lung Neoplasms.
RITSUKO KOMAKI
Connection Strength
7.583
Lung Neoplasms
  1. Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment? Radiother Oncol. 2018 06; 127(3):339-343.
    View in: PubMed
    Score: 0.131
  2. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018 Mar; 126(3):499-505.
    View in: PubMed
    Score: 0.129
  3. Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer. Am J Clin Oncol. 2017 Dec; 40(6):625-630.
    View in: PubMed
    Score: 0.128
  4. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017 11; 12(11):1696-1703.
    View in: PubMed
    Score: 0.125
  5. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: Do all patients benefit? Radiother Oncol. 2017 02; 122(2):307-312.
    View in: PubMed
    Score: 0.120
  6. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.107
  7. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. Radiother Oncol. 2014 Jul; 112(1):30-6.
    View in: PubMed
    Score: 0.101
  8. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014 Mar 15; 120(6):790-8.
    View in: PubMed
    Score: 0.097
  9. What would be the most appropriate a/? ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. Biomed Res Int. 2013; 2013:391021.
    View in: PubMed
    Score: 0.096
  10. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy. PLoS One. 2013; 8(4):e59729.
    View in: PubMed
    Score: 0.092
  11. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1082-9.
    View in: PubMed
    Score: 0.091
  12. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e531-6.
    View in: PubMed
    Score: 0.087
  13. Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases. PLoS One. 2012; 7(4):e35809.
    View in: PubMed
    Score: 0.087
  14. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol. 2012 Mar 15; 7:33.
    View in: PubMed
    Score: 0.086
  15. A prospective phase 2 study of surgery followed by chemotherapy and radiation for superior sulcus tumors. Cancer. 2012 Jan 15; 118(2):444-51.
    View in: PubMed
    Score: 0.082
  16. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol. 2011 Jun 10; 29(17):2312-8.
    View in: PubMed
    Score: 0.081
  17. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non?small-cell lung cancer or lung metastases. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):856-62.
    View in: PubMed
    Score: 0.079
  18. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy. J Radiat Res. 2010; 51(4):465-71.
    View in: PubMed
    Score: 0.076
  19. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. Radiother Oncol. 2010 Jan; 94(1):1-11.
    View in: PubMed
    Score: 0.074
  20. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):802-8.
    View in: PubMed
    Score: 0.071
  21. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009 Feb; 4(2):179-84.
    View in: PubMed
    Score: 0.069
  22. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):967-71.
    View in: PubMed
    Score: 0.068
  23. Validation of a model-based segmentation approach to propagating normal anatomic regions of interest through the 10 phases of respiration. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):900-6.
    View in: PubMed
    Score: 0.066
  24. Neurocognitive function in patients with small cell lung cancer : effect of prophylactic cranial irradiation. Cancer. 2008 Feb 01; 112(3):589-95.
    View in: PubMed
    Score: 0.065
  25. Image-guided radiation therapy for non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):177-86.
    View in: PubMed
    Score: 0.065
  26. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):779-85.
    View in: PubMed
    Score: 0.061
  27. Reduction of normal lung irradiation in locally advanced non-small-cell lung cancer patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys. 2007 Jun 01; 68(2):562-71.
    View in: PubMed
    Score: 0.061
  28. Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1036-46.
    View in: PubMed
    Score: 0.061
  29. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):94-102.
    View in: PubMed
    Score: 0.060
  30. Endobronchial brachytherapy: an effective option for palliation of malignant bronchial obstruction. Clin Lung Cancer. 2006 Nov; 8(3):203-7.
    View in: PubMed
    Score: 0.059
  31. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1399-407.
    View in: PubMed
    Score: 0.059
  32. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):100-7.
    View in: PubMed
    Score: 0.058
  33. Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer. Clin Lung Cancer. 2006 Jan; 7(4):282-4.
    View in: PubMed
    Score: 0.056
  34. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy? J Clin Oncol. 2005 Oct 01; 23(28):7232-3; author reply 7233-5.
    View in: PubMed
    Score: 0.055
  35. Quantification of regional ventilation from treatment planning CT. Int J Radiat Oncol Biol Phys. 2005 Jul 01; 62(3):630-4.
    View in: PubMed
    Score: 0.054
  36. Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. Curr Oncol Rep. 2005 Jul; 7(4):255-9.
    View in: PubMed
    Score: 0.054
  37. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):342-50.
    View in: PubMed
    Score: 0.054
  38. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8.
    View in: PubMed
    Score: 0.053
  39. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
    View in: PubMed
    Score: 0.049
  40. Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 1):47-53.
    View in: PubMed
    Score: 0.049
  41. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12.
    View in: PubMed
    Score: 0.049
  42. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081.
    View in: PubMed
    Score: 0.048
  43. Combined treatment for limited small cell lung cancer. Semin Oncol. 2003 Aug; 30(4 Suppl 9):56-70.
    View in: PubMed
    Score: 0.047
  44. Target definition and contouring in carcinoma of the lung and esophagus. Rays. 2003 Jul-Sep; 28(3):225-36.
    View in: PubMed
    Score: 0.047
  45. Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):114-20.
    View in: PubMed
    Score: 0.046
  46. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023 05 01; 41(13):2394-2402.
    View in: PubMed
    Score: 0.045
  47. Oncodiagnosis panel: 1999. Cancer of the lung: oncodiagnosis. Radiographics. 2001 Nov-Dec; 21(6):1573-96.
    View in: PubMed
    Score: 0.042
  48. Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. Lung Cancer. 2021 06; 156:68-71.
    View in: PubMed
    Score: 0.040
  49. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer. 2021 05; 22(3):225-233.e7.
    View in: PubMed
    Score: 0.038
  50. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol. 2020 04; 43(4):231-235.
    View in: PubMed
    Score: 0.037
  51. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. JAMA Netw Open. 2020 04 01; 3(4):e201929.
    View in: PubMed
    Score: 0.037
  52. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 03 01; 38(7):706-714.
    View in: PubMed
    Score: 0.037
  53. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.036
  54. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis. Radiat Oncol. 2018 Dec 29; 13(1):258.
    View in: PubMed
    Score: 0.034
  55. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 04 01; 103(5):1077-1084.
    View in: PubMed
    Score: 0.034
  56. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clin Lung Cancer. 2019 03; 20(2):117-123.
    View in: PubMed
    Score: 0.034
  57. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. 2019 02 01; 125(3):382-390.
    View in: PubMed
    Score: 0.034
  58. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer. 2018 11; 19(6):e885-e891.
    View in: PubMed
    Score: 0.034
  59. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018 08 01; 4(8):e174504.
    View in: PubMed
    Score: 0.033
  60. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018 09; 128(3):505-512.
    View in: PubMed
    Score: 0.033
  61. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Med. 2018 06; 7(6):2247-2255.
    View in: PubMed
    Score: 0.033
  62. Clinical and Dosimetric Factors Predicting Grade =2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):919-926.
    View in: PubMed
    Score: 0.033
  63. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018 06; 27(6):1563-1570.
    View in: PubMed
    Score: 0.033
  64. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563.
    View in: PubMed
    Score: 0.032
  65. Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol. 2018 05; 13(5):660-675.
    View in: PubMed
    Score: 0.032
  66. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.032
  67. Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Non-Small Cell Lung Cancer Using Conditional Survival Analysis. Am J Clin Oncol. 2018 Jan; 41(1):46-52.
    View in: PubMed
    Score: 0.032
  68. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.
    View in: PubMed
    Score: 0.032
  69. RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer. Clin Cancer Res. 2018 01 15; 24(2):341-350.
    View in: PubMed
    Score: 0.032
  70. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):452-461.
    View in: PubMed
    Score: 0.032
  71. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.031
  72. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5948-5958.
    View in: PubMed
    Score: 0.031
  73. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 04; 15(4):504-535.
    View in: PubMed
    Score: 0.030
  74. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.030
  75. Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992.
    View in: PubMed
    Score: 0.030
  76. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017 02; 122(2):274-280.
    View in: PubMed
    Score: 0.030
  77. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907.
    View in: PubMed
    Score: 0.030
  78. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
    View in: PubMed
    Score: 0.030
  79. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2017 Jan; 35(1):56-62.
    View in: PubMed
    Score: 0.030
  80. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.030
  81. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
    View in: PubMed
    Score: 0.029
  82. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36.
    View in: PubMed
    Score: 0.029
  83. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clin Cancer Res. 2016 Dec 01; 22(23):5876-5886.
    View in: PubMed
    Score: 0.029
  84. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncol. 2016 Aug; 55(8):1022-8.
    View in: PubMed
    Score: 0.028
  85. MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. PLoS One. 2016; 11(3):e0150467.
    View in: PubMed
    Score: 0.028
  86. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial. JAMA Oncol. 2016 Mar; 2(3):359-67.
    View in: PubMed
    Score: 0.028
  87. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 03; 14(3):255-64.
    View in: PubMed
    Score: 0.028
  88. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
    View in: PubMed
    Score: 0.028
  89. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016 Jan; 108(1).
    View in: PubMed
    Score: 0.028
  90. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J. 2015 Dec; 46(6):1751-61.
    View in: PubMed
    Score: 0.027
  91. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 2015 Nov 15; 93(4):757-64.
    View in: PubMed
    Score: 0.027
  92. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72.
    View in: PubMed
    Score: 0.027
  93. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24.
    View in: PubMed
    Score: 0.027
  94. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015 Mar 02; (3):CD011430.
    View in: PubMed
    Score: 0.026
  95. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb; 16(2):187-99.
    View in: PubMed
    Score: 0.026
  96. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014 Dec 08; 15:1079.
    View in: PubMed
    Score: 0.026
  97. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61.
    View in: PubMed
    Score: 0.026
  98. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014 Dec; 113(3):379-84.
    View in: PubMed
    Score: 0.026
  99. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
    View in: PubMed
    Score: 0.026
  100. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27.
    View in: PubMed
    Score: 0.026
  101. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e259-68.
    View in: PubMed
    Score: 0.025
  102. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
    View in: PubMed
    Score: 0.025
  103. Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial. Radiat Oncol. 2014 May 06; 9:108.
    View in: PubMed
    Score: 0.025
  104. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014 Aug; 22(8):1494-1503.
    View in: PubMed
    Score: 0.025
  105. Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Eur J Cancer. 2014 Jul; 50(10):1706-1716.
    View in: PubMed
    Score: 0.025
  106. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone". Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1120-8.
    View in: PubMed
    Score: 0.025
  107. Failure patterns relative to radiation treatment fields for stage II-IV thymoma. J Thorac Oncol. 2014 Mar; 9(3):403-9.
    View in: PubMed
    Score: 0.025
  108. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol. 2014 Mar; 110(3):493-8.
    View in: PubMed
    Score: 0.025
  109. Prognostic value of positron emission tomography/computed tomography findings in limited-stage small cell lung cancer before chemoradiation therapy. Am J Clin Oncol. 2014 Feb; 37(1):77-80.
    View in: PubMed
    Score: 0.024
  110. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):319-25.
    View in: PubMed
    Score: 0.024
  111. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014 Feb; 41(2):021721.
    View in: PubMed
    Score: 0.024
  112. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013 Oct 20; 31(30):3823-30.
    View in: PubMed
    Score: 0.024
  113. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013 Oct; 109(1):38-44.
    View in: PubMed
    Score: 0.024
  114. Cardiac ?8F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013 Oct; 109(1):82-8.
    View in: PubMed
    Score: 0.024
  115. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.024
  116. Reply to v.R. Bhatt et Al and m.C. Chamberlain. J Clin Oncol. 2013 Sep 01; 31(25):3165-6.
    View in: PubMed
    Score: 0.024
  117. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10.
    View in: PubMed
    Score: 0.023
  118. TGF?1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. PLoS One. 2013; 8(6):e65659.
    View in: PubMed
    Score: 0.023
  119. Patterns of practice in radiation therapy for non-small cell lung cancer among members of the American Society for Radiation Oncology. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):e133-e141.
    View in: PubMed
    Score: 0.023
  120. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):645-53; quiz 653.
    View in: PubMed
    Score: 0.023
  121. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70.
    View in: PubMed
    Score: 0.023
  122. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1312-8.
    View in: PubMed
    Score: 0.023
  123. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1332-9.
    View in: PubMed
    Score: 0.023
  124. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
    View in: PubMed
    Score: 0.023
  125. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447.
    View in: PubMed
    Score: 0.023
  126. ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):1066-73.
    View in: PubMed
    Score: 0.022
  127. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1236-71.
    View in: PubMed
    Score: 0.022
  128. Association between single nucleotide polymorphisms of the transforming growth factor ?1 gene and the risk of severe radiation esophagitis in patients with lung cancer. Radiother Oncol. 2012 Dec; 105(3):299-304.
    View in: PubMed
    Score: 0.022
  129. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152.
    View in: PubMed
    Score: 0.022
  130. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012 Aug 28; 7:144.
    View in: PubMed
    Score: 0.022
  131. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1010-6.
    View in: PubMed
    Score: 0.022
  132. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 2012 Aug; 7(8):1211-7.
    View in: PubMed
    Score: 0.022
  133. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1573-9.
    View in: PubMed
    Score: 0.022
  134. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.022
  135. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1558-65.
    View in: PubMed
    Score: 0.022
  136. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1017-23.
    View in: PubMed
    Score: 0.022
  137. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1093-100.
    View in: PubMed
    Score: 0.022
  138. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e61-7.
    View in: PubMed
    Score: 0.022
  139. Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma. J Thorac Oncol. 2012 Apr; 7(4):716-22.
    View in: PubMed
    Score: 0.022
  140. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e537-43.
    View in: PubMed
    Score: 0.021
  141. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e391-8.
    View in: PubMed
    Score: 0.021
  142. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 2012 Mar 15; 18(6):1641-54.
    View in: PubMed
    Score: 0.021
  143. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer. J Nucl Med. 2012 Feb; 53(2):225-33.
    View in: PubMed
    Score: 0.021
  144. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.
    View in: PubMed
    Score: 0.021
  145. TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2011 Oct 14; 11:447.
    View in: PubMed
    Score: 0.021
  146. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 05; 103(19):1452-60.
    View in: PubMed
    Score: 0.021
  147. Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiological modeling and clinical outcome. Am J Clin Oncol. 2011 Aug; 34(4):432-41.
    View in: PubMed
    Score: 0.021
  148. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer. 2012 Jan 15; 118(2):528-35.
    View in: PubMed
    Score: 0.020
  149. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):e91-7.
    View in: PubMed
    Score: 0.020
  150. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13.
    View in: PubMed
    Score: 0.020
  151. Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):e67-73.
    View in: PubMed
    Score: 0.020
  152. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.
    View in: PubMed
    Score: 0.020
  153. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1350-7.
    View in: PubMed
    Score: 0.020
  154. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim. 2011; 36(4):383-8.
    View in: PubMed
    Score: 0.020
  155. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):425-34.
    View in: PubMed
    Score: 0.019
  156. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):77-84.
    View in: PubMed
    Score: 0.019
  157. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.
    View in: PubMed
    Score: 0.019
  158. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010 Aug 16; 10:431.
    View in: PubMed
    Score: 0.019
  159. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul; 8(7):740-801.
    View in: PubMed
    Score: 0.019
  160. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):91-6.
    View in: PubMed
    Score: 0.019
  161. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst. 2010 Jun 16; 102(12):859-65.
    View in: PubMed
    Score: 0.019
  162. The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials. J Thorac Oncol. 2010 May; 5(5):631-9.
    View in: PubMed
    Score: 0.019
  163. Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):473-80.
    View in: PubMed
    Score: 0.019
  164. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1387-93.
    View in: PubMed
    Score: 0.019
  165. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74.
    View in: PubMed
    Score: 0.019
  166. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol. 2009 Dec 01; 27(34):5816-22.
    View in: PubMed
    Score: 0.018
  167. Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2010 Jul 01; 77(3):691-8.
    View in: PubMed
    Score: 0.018
  168. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. 2010 Jun 01; 77(2):357-66.
    View in: PubMed
    Score: 0.018
  169. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res. 2009 Aug 01; 15(15):4829-37.
    View in: PubMed
    Score: 0.018
  170. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer? Cancer. 2009 Jul 15; 115(14):3233-42.
    View in: PubMed
    Score: 0.018
  171. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg. 2009 Jul; 75(7):598-603; discussion 603-4.
    View in: PubMed
    Score: 0.018
  172. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81.
    View in: PubMed
    Score: 0.018
  173. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg. 2009 Jun; 137(6):1379-87.
    View in: PubMed
    Score: 0.018
  174. Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009 Jul 10; 27(20):3370-8.
    View in: PubMed
    Score: 0.018
  175. ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent. J Am Coll Radiol. 2009 Feb; 6(2):85-95.
    View in: PubMed
    Score: 0.017
  176. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiat Oncol. 2009 Jan 30; 4:5.
    View in: PubMed
    Score: 0.017
  177. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res. 2008 Dec 01; 14(23):7832-7.
    View in: PubMed
    Score: 0.017
  178. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest. 2008 Dec; 134(6):1349.
    View in: PubMed
    Score: 0.017
  179. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. Radiother Oncol. 2009 Jun; 91(3):427-32.
    View in: PubMed
    Score: 0.017
  180. Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):94-102.
    View in: PubMed
    Score: 0.017
  181. Analysis of radiation pneumonitis risk using a generalized Lyman model. Int J Radiat Oncol Biol Phys. 2008 Oct 01; 72(2):568-74.
    View in: PubMed
    Score: 0.017
  182. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008 Aug; 3(8):858-64.
    View in: PubMed
    Score: 0.017
  183. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):119-27.
    View in: PubMed
    Score: 0.017
  184. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1378-84.
    View in: PubMed
    Score: 0.016
  185. Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1385-95.
    View in: PubMed
    Score: 0.016
  186. Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review. J Thorac Oncol. 2008 May; 3(5):534-8.
    View in: PubMed
    Score: 0.016
  187. Imaging of non-small cell lung cancer of the superior sulcus: part 1: anatomy, clinical manifestations, and management. Radiographics. 2008 Mar-Apr; 28(2):551-60; quiz 620.
    View in: PubMed
    Score: 0.016
  188. Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging and assessment of resectability and therapeutic response. Radiographics. 2008 Mar-Apr; 28(2):561-72.
    View in: PubMed
    Score: 0.016
  189. Non-small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):228-69.
    View in: PubMed
    Score: 0.016
  190. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. J Thorac Oncol. 2007 Nov; 2(11):1022-8.
    View in: PubMed
    Score: 0.016
  191. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1409-16.
    View in: PubMed
    Score: 0.016
  192. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Dec 01; 69(5):1534-43.
    View in: PubMed
    Score: 0.016
  193. Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2007 Aug 01; 68(5):1349-58.
    View in: PubMed
    Score: 0.015
  194. Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. Int J Radiat Oncol Biol Phys. 2007 Jun 01; 68(2):531-40.
    View in: PubMed
    Score: 0.015
  195. 4D Proton treatment planning strategy for mobile lung tumors. Int J Radiat Oncol Biol Phys. 2007 Mar 01; 67(3):906-14.
    View in: PubMed
    Score: 0.015
  196. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):111-8.
    View in: PubMed
    Score: 0.015
  197. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007 Feb; 6(2):471-83.
    View in: PubMed
    Score: 0.015
  198. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. (Int J Radiat Oncol Biol Phys 2006;65:640-645). Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1595-6; author reply 1596.
    View in: PubMed
    Score: 0.015
  199. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol. 2006 Sep 20; 24(27):4485-91.
    View in: PubMed
    Score: 0.015
  200. Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Sep 01; 66(1):108-16.
    View in: PubMed
    Score: 0.015
  201. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol. 2006 Aug 01; 24(22):3597-603.
    View in: PubMed
    Score: 0.015
  202. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul; 4(6):548-82.
    View in: PubMed
    Score: 0.014
  203. Surgical patterns of care in operable lung carcinoma treated with radiation. J Thorac Oncol. 2006 Jul; 1(6):526-31.
    View in: PubMed
    Score: 0.014
  204. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1087-96.
    View in: PubMed
    Score: 0.014
  205. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer. 2006 May 01; 106(9):1998-2004.
    View in: PubMed
    Score: 0.014
  206. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution. J Thorac Cardiovasc Surg. 2005 Dec; 130(6):1601-10.
    View in: PubMed
    Score: 0.014
  207. Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6657-68.
    View in: PubMed
    Score: 0.014
  208. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):667-71.
    View in: PubMed
    Score: 0.013
  209. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol. 2005 May 20; 23(15):3480-7.
    View in: PubMed
    Score: 0.013
  210. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8.
    View in: PubMed
    Score: 0.013
  211. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res. 2005 Apr 15; 11(8):2894-8.
    View in: PubMed
    Score: 0.013
  212. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature? Lung Cancer. 2005 Apr; 48(1):93-102.
    View in: PubMed
    Score: 0.013
  213. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005 Apr 01; 23(10):2145-54.
    View in: PubMed
    Score: 0.013
  214. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1136-43.
    View in: PubMed
    Score: 0.013
  215. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):318-28.
    View in: PubMed
    Score: 0.013
  216. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer. 2005 Jun; 48(3):389-97.
    View in: PubMed
    Score: 0.013
  217. Preoperative and postoperative irradiation for cancer of the lung. J Belge Radiol. 1985; 68(3):195-8.
    View in: PubMed
    Score: 0.013
  218. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part I--correlating internal lung motion with skin fiducial motion. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1459-72.
    View in: PubMed
    Score: 0.013
  219. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II-margin reduction of internal target volume. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1473-83.
    View in: PubMed
    Score: 0.013
  220. Radiation dose escalation in non-small cell carcinoma of the lung. Semin Radiat Oncol. 2004 Oct; 14(4):287-91.
    View in: PubMed
    Score: 0.013
  221. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg. 2004 Jul; 128(1):130-7.
    View in: PubMed
    Score: 0.013
  222. Epidermal growth factor receptor as a target to improve treatment of lung cancer. Clin Lung Cancer. 2004 May; 5(6):340-52.
    View in: PubMed
    Score: 0.012
  223. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1258-67.
    View in: PubMed
    Score: 0.012
  224. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1268-79.
    View in: PubMed
    Score: 0.012
  225. Dosimetric benefits of respiratory gating: a preliminary study. J Appl Clin Med Phys. 2004; 5(1):16-24.
    View in: PubMed
    Score: 0.012
  226. Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer. Lung Cancer. 2003 Oct; 42(1):79-86.
    View in: PubMed
    Score: 0.012
  227. Treatment planning for lung cancer: traditional homogeneous point-dose prescription compared with heterogeneity-corrected dose-volume prescription. Int J Radiat Oncol Biol Phys. 2003 Aug 01; 56(5):1308-18.
    View in: PubMed
    Score: 0.012
  228. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol. 2003 Aug; 26(4):S85-91.
    View in: PubMed
    Score: 0.012
  229. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003 Jul 01; 21(13):2529-36.
    View in: PubMed
    Score: 0.012
  230. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):17-21.
    View in: PubMed
    Score: 0.012
  231. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.012
  232. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res. 2003 Jun; 9(6):2085-91.
    View in: PubMed
    Score: 0.012
  233. The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):106-13.
    View in: PubMed
    Score: 0.012
  234. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. Clin Cancer Res. 2003 Mar; 9(3):1070-6.
    View in: PubMed
    Score: 0.011
  235. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.011
  236. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1216-24.
    View in: PubMed
    Score: 0.011
  237. Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 01; 52(2):362-70.
    View in: PubMed
    Score: 0.011
  238. Brachytherapy for carcinoma of the lung. Oncology (Williston Park). 2001 Mar; 15(3):371-81.
    View in: PubMed
    Score: 0.010
  239. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203.
    View in: PubMed
    Score: 0.007
  240. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol. 2011 Jun 20; 29(18):2590-7.
    View in: PubMed
    Score: 0.005
  241. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer. 2009 Jul 01; 115(13):2930-8.
    View in: PubMed
    Score: 0.004
  242. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg. 2009 Aug; 138(2):412-418.e1-2.
    View in: PubMed
    Score: 0.004
  243. Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. Int J Radiat Oncol Biol Phys. 2008 Sep 01; 72(1):210-9.
    View in: PubMed
    Score: 0.004
  244. Heterogeneous planning for homogeneous protocols. Med Dosim. 2004; 29(2):80-4.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.